OTC · ACORQ
Acorda Therapeutics, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$0.01
Down-$0.00 (-24.81%)
Updated Aug 24, 2026, 1:52 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 12.42K
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 15.6K
- Avg. volume
- 14.58K
Price performance
ACORQ price history
1M range · 0 trading sessions · Daily adjusted prices
ACORQ does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest ACORQ news
The latest Smart Investors Daily articles mentioning ACORQ.
Stock researchCompany · Overview
ACORQ research
Overview
Company profile and research snapshot.
Company profile
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
